Your browser doesn't support javascript.
loading
One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS.
Ramharter, Juergen; Kessler, Dirk; Ettmayer, Peter; Hofmann, Marco H; Gerstberger, Thomas; Gmachl, Michael; Wunberg, Tobias; Kofink, Christiane; Sanderson, Michael; Arnhof, Heribert; Bader, Gerd; Rumpel, Klaus; Zöphel, Andreas; Schnitzer, Renate; Böttcher, Jark; O'Connell, Jonathan C; Mendes, Rachel L; Richard, David; Pototschnig, Nikolai; Weiner, Irene; Hela, Wolfgang; Hauer, Katja; Haering, Daniela; Lamarre, Lyne; Wolkerstorfer, Bernhard; Salamon, Christian; Werni, Patrick; Munico-Martinez, Silvia; Meyer, Reiner; Kennedy, Matthew D; Kraut, Norbert; McConnell, Darryl B.
Afiliação
  • Ramharter J; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Kessler D; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Ettmayer P; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Hofmann MH; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Gerstberger T; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Gmachl M; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Wunberg T; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Kofink C; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Sanderson M; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Arnhof H; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Bader G; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Rumpel K; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Zöphel A; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Schnitzer R; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Böttcher J; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • O'Connell JC; Forma Therapeutics, 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472, United States.
  • Mendes RL; Forma Therapeutics, 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472, United States.
  • Richard D; Forma Therapeutics, 500 Arsenal Street, Suite 100, Watertown, Massachusetts 02472, United States.
  • Pototschnig N; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Weiner I; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Hela W; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Hauer K; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Haering D; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Lamarre L; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Wolkerstorfer B; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Salamon C; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Werni P; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Munico-Martinez S; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Meyer R; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Kennedy MD; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • Kraut N; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
  • McConnell DB; Boehringer Ingelheim RCV GmbH & Co KG, Dr. Boehringer-Gasse 5-11, A-1121 Vienna, Austria.
J Med Chem ; 64(10): 6569-6580, 2021 05 27.
Article em En | MEDLINE | ID: mdl-33719426
ABSTRACT
KRAS, the most common oncogenic driver in human cancers, is controlled and signals primarily through protein-protein interactions (PPIs). The interaction between KRAS and SOS1, crucial for the activation of KRAS, is a typical, challenging PPI with a large contact surface area and high affinity. Here, we report that the addition of only one atom placed between Y884SOS1 and A73KRAS is sufficient to convert SOS1 activators into SOS1 inhibitors. We also disclose the discovery of BI-3406. Combination with the upstream EGFR inhibitor afatinib shows in vivo efficacy against KRASG13D mutant colorectal tumor cells, demonstrating the utility of BI-3406 to probe SOS1 biology. These findings challenge the dogma that large molecules are required to disrupt challenging PPIs. Instead, a "foot in the door" approach, whereby single atoms or small functional groups placed between key PPI interactions, can lead to potent inhibitors even for challenging PPIs such as SOS1-KRAS.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas p21(ras) / Proteína SOS1 Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Proto-Oncogênicas p21(ras) / Proteína SOS1 Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article